Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 104, Issue 4, 2007, Pages

  Srisubut, Suthasiny ^a   Teerakapong, Arun ^a   Vattraphodes, Theparith ^a   Taweechaisupapong, Suwimol ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOGRAN; BIOMATERIAL; BONE DENSITY CONSERVATION AGENT; GLASS; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BONE PROSTHESIS; BONE REGENERATION; DRUG EFFECT; MALE; MANDIBLE; OSTEOCLAST; RAT; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ALENDRONATE; ANIMALS; BIOCOMPATIBLE MATERIALS; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; BONE SUBSTITUTES; GLASS; MALE; MANDIBLE; OSTEOCLASTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34648827420     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2007.04.022     Document Type: Article

References (44)

1. Leonetti J.A., Rambo H.M., and Throndson R.R. Osteotome sinus elevation and implant placement with narrow size bioactive glass. Implant Dent 9 (2000) 177-182
2. Schepers E.J., and Ducheyne P. Bioactive glass particles of narrow size range for the treatment of oral bone defects: a 1-24 month experiment with several materials and particle sizes and size ranges. J Oral Rehabil 24 (1997) 171-181
3. Furusawa T., Mizunuma K., Yamashita S., and Takahashi T. Investigation of early bone formation using resorbable bioactive glass in the rat mandible. Int J Oral Maxillofac Implants 13 (1998) 672-676
4. Furusawa T., and Mizunuma K. Osteoconductive properties and efficacy of resorbable bioactive glass as a bone-grafting material. Implant Dent 6 (1997) 93-101
5. Binderman I. Bone and biologically compatible materials in dentistry. Curr Opin Dent 1 (1991) 836-840
6. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 32 (1992) 160-167
7. Baylink D.J., Finkelman R.D., and Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 8 (1993) S565-S572
8. Adami S., Zamberlan N., Mian M., Dorizzi R., Rossini M., Braga B., et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 25 (1994) 75-82
9. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
10. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095-2105
11. Yaffe A., Iztkovich M., Earon Y., Alt I., Lilov R., and Binderman I. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 68 (1997) 884-889
12. Yaffe A., Fine N., Alt I., and Binderman I. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 66 (1995) 999-1003
13. Schenk R., Eggli P., Fleisch H., and Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38 (1986) 342-349
14. Kaynak D., Meffert R., Gunhan M., Gunhan O., and Ozkaya O. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 71 (2000) 790-796
15. Masarachia P., Weinreb M., Balena R., and Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19 (1996) 281-290
16. Yaffe A., Binderman I., Breuer E., Pinto T., and Golomb G. Disposition of alendronate following local delivery in a rat jaw. J Periodontol 70 (1999) 893-895
17. Astrand J., and Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 22 (2004) 244-249
18. Leite A.F., Figueiredo P.T., Melo N.S., Acevedo A.C., Cavalcanti M.G., Paula L.M., et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 14-21
19. Robinson N.A., and Yeo J.F. Bisphosphonates-a word of caution. Ann Acad Med Singapore 33 (2004) 48-49
20. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61 (2003) 1238-1239
21. Agarwala S., Sule A., Pai B.U., and Joshi V.R. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxf) 41 (2002) 346-347
22. Astrand J., and Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 3 (2002) 19
23. Kaban L.B., and Glowacki J. Induced osteogenesis in the repair of experimental mandibular defects in rats. J Dent Res 60 (1981) 1356-1364
24. Luna L. Manual of histologic staining methods of the Armed Forces Institute of Pathology. 3rd ed. (1968), McGraw, New York 94-95
25. Matsuda T., and Davies J.E. The in vitro response of osteoblasts to bioactive glass. Biomaterials 8 (1987) 275-284
26. Hench L.L., and Paschall H.A. Histochemical responses at a biomaterial's interface. J Biomed Mater Res 8 (1974) 49-64
27. Zamet J.S., Darbar U.R., Griffiths G.S., Bulman J.S., Bragger U., Burgin W., et al. Particulate bioglass as a grafting material in the treatment of periodontal intrabony defects. J Clin Periodontol 24 (1997) 410-418
28. Low S.B., King C.J., and Krieger J. An evaluation of bioactive ceramic in the treatment of periodontal osseous defects. Int J Periodontics Restor Dent 17 (1997) 358-367
29. Hench L.L., and Paschall H.A. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. J Biomed Mater Res 7 (1973) 25-42
30. Wilson J., Clark A.E., Hall M., and Hench L.L. Tissue response to Bioglass endosseous ridge maintenance implants. J Oral Implantol 19 (1993) 295-302
31. Villaca J.H., Novaes Jr. A.B., Souza S.L., Taba Jr. M., Molina G.O., and Carvalho T.L. Bioactive glass efficacy in the periodontal healing of intrabony defects in monkeys. Braz Dent J 16 (2005) 67-74
32. Higuchi T., Kinoshita A., Takahashi K., Oda S., and Ishikawa I. Bone regeneration by recombinant human bone morphogenetic protein-2 in rat mandibular defects. An experimental model of defect filling. J Periodontol 70 (1999) 1026-1031
33. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 (2000) 115-137
34. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 (1998) 80-100
35. Tenenbaum H.C., Torontali M., and Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13 (1992) 249-255
36. Goziotis A., Sukhu B., Torontali M., Dowhaniuk M., and Tenenbaum H.C. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 16 (1995) 317S-327S
37. Giuliani N., Pedrazzoni M., Negri G., Passeri G., Impicciatore M., and Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22 (1998) 455-461
38. Vitte C., Fleisch H., and Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137 (1996) 2324-2333
39. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., and Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104 (1999) 1363-1374
40. Meraw S.J., and Reeve C.M. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol 70 (1999) 1228-1233
41. Tenenbaum H.C., Shelemay A., Girard B., Zohar R., and Fritz P.C. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 73 (2002) 813-822
42. Bone H.G., Adami S., Rizzoli R., Favus M., Ross P.D., Santora A., et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 22 (2000) 15-28
43. Vasikaran S.D. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38 (2001) 608-623
44. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534